The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma

被引:32
|
作者
Lu, Hongsheng [1 ]
Yang, Zhaohui [1 ]
Zhang, Hui [1 ]
Gan, Meifu [2 ]
Zhou, Tao [2 ]
Wang, Siling [1 ]
机构
[1] Taizhou Enze Med Grp, Taizhou Cent Hosp, Dept Pathol, Taizhou 318000, Zhejiang, Peoples R China
[2] Taizhou Enze Med Grp, Taizhou Hosp, Dept Pathol, Linhai 317000, Peoples R China
关键词
clear cell renal cell carcinoma; matrix metalloproteinase 7; tissue inhibitor of matrix metalloproteinases 2; prognosis; tissue microarray; CANCER; INVASION; POLYMORPHISMS; PROTEASES;
D O I
10.3892/etm.2012.859
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Renal cell carcinoma (RCC) is one of the most common malignant neoplasms in the urinary system, and has a high frequency of local invasion and distant metastasis. This study assessed the expression and clinical significance of matrix metalloproteinase 7 (MMP-7) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in human clear cell renal cell carcinoma (CCRCC) by tissue microarray, immunohistochemistry and RT-PCR analysis. The expression of MMP-7 in CCRCC tissues was significantly higher compared with that in the control group (CG) and TIMP-2 expression in CCRCC, by contrast, was lower compared with that in the CG. The expression of MMP-7 and TIMP-2 in the CCRCC tissues was significantly correlated with the pathological grade and clinical stage. Log-rank analyses indicated that upregulation of MMP-7 and downregulation of TIMP-2 expression may occur during the progression of CCRCC, and Cox multivariate survival rate analysis demonstrated that there was also a positive correlation between the pathological grade, clinical stage, MMP-7 expression and survival rate. Thus, MMP-7 is an independent prognostic factor and MMP-7 and TIMP-2 may serve as useful molecular markers for evaluating prognosis in CCRCC patients.
引用
收藏
页码:890 / 896
页数:7
相关论文
共 50 条
  • [21] Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-2 in human endometrial carcinoma
    陈梅
    薄乃秀
    黄亚军
    戴琪
    巩丽梅
    生殖医学杂志, 2010, 19(S2) (S2) : 59 - 63
  • [22] Inhibition of extracellular matrix metalloproteinase inducer expression reduces clear cell renal carcinoma cell invasion and metastasis
    Zhang, Zhen
    Shao, Zhiqiang
    Wang, Kai
    Wang, Guangjian
    He, Xiangfei
    Guo, Fengfu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (10): : 10105 - 10116
  • [23] Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential
    Miyake, H
    Hara, I
    Gohji, K
    Yamanaka, K
    Hara, S
    Arakawa, S
    Nakajima, M
    Kamidono, S
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 2824 - 2829
  • [24] Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma
    Takahashi, M
    Oka, N
    Naroda, T
    Nishitani, MA
    Kanda, K
    Kanayama, HO
    Kagawa, S
    INTERNATIONAL JOURNAL OF UROLOGY, 2002, 9 (10) : 531 - 538
  • [25] Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma
    Gu, Zhen-Dong
    Chen, Ke-Neng
    Li, Ming
    Gu, Jin
    Li, Ji-You
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (06) : 871 - 874
  • [27] Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary
    Okamoto, T
    Niu, R
    Yamada, S
    MOLECULAR HUMAN REPRODUCTION, 2003, 9 (10) : 569 - 575
  • [28] Clinical evaluation for matrix metalloproteinases family expression in renal cell carcinoma: An immunohistochemical analysis
    Kawata, N
    Nagane, Y
    Yagasaki, H
    Morita, K
    Igarashi, T
    Ichinose, T
    Hirakata, H
    Hachiya, T
    Takimoto, Y
    JOURNAL OF UROLOGY, 2005, 173 (04): : 265 - 265
  • [29] Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib
    Miyake, Hideaki
    Nishikawa, Masatomo
    Tei, Hiromoto
    Furukawa, Junya
    Harada, Ken-ichi
    Fujisawa, Masato
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 584 - 588
  • [30] Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma
    Imanishi, Y
    Fujii, M
    Tokumaru, Y
    Tomita, T
    Kanke, M
    Kanzaki, J
    Kameyama, K
    Otani, Y
    Sato, H
    HUMAN PATHOLOGY, 2000, 31 (08) : 895 - 904